Mild Cognitive Impairment — Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures
Citation(s)
10 McLeod, D.R., et al., An automated version of the digit symbol substitution test (DSST). Behavior Research Methods & Instrumentation, 1982. 14(5): p. 463-466.
Barker J, Smith Byrne K, Doherty A, Foster C, Rahimi K, Ramakrishnan R, Woodward M, Dwyer T Physical activity of UK adults with chronic disease: cross-sectional analysis of accelerometer-measured physical activity in 96 706 UK Biobank participants. Int J Epidemiol. 2019 Aug 1;48(4):1167-1174. doi: 10.1093/ije/dyy294. Erratum In: Int J Epidemiol. 2019 Aug 1;48(4):1386.
Bertens D, Tijms BM, Vermunt L, Prins ND, Scheltens P, Visser PJ The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. Alzheimers Dement (N Y). 2017 Sep 21;3(4):513-523. doi: 10.1016/j.trci.2017.08.005. eCollection 2017 Nov.
Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990 Dec;157:853-9. doi: 10.1192/bjp.157.6.853.
Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.
Hughes TF, Chang CC, Vander Bilt J, Ganguli M Engagement in reading and hobbies and risk of incident dementia: the MoVIES project. Am J Alzheimers Dis Other Demen. 2010 Aug;25(5):432-8. doi: 10.1177/1533317510368399.
Koster N, Knol DL, Uitdehaag BM, Scheltens P, Sikkes SA The sensitivity to change over time of the Amsterdam IADL Questionnaire((c)). Alzheimers Dement. 2015 Oct;11(10):1231-40. doi: 10.1016/j.jalz.2014.10.006. Epub 2015 Jan 15.
Miller, N E., et al., Accuracy Of Behavioral Assessment With A Wearable Camera in Semi-structured And Free Living Conditions In Older Adults. Medicine and Science in Sports and Exercise, 2017. 49(5): p. 651-651.
Narayan VA, Manji HK Moving from 'diagnose and treat' to 'predict and pre-empt' in neuropsychiatric disorders. Nat Rev Drug Discov. 2016 Feb;15(2):71-2. doi: 10.1038/nrd.2015.20. Epub 2015 Nov 27.
Oldfield RC The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971 Mar;9(1):97-113. doi: 10.1016/0028-3932(71)90067-4. No abstract available.
Ries JD, Echternach JL, Nof L, Gagnon Blodgett M Test-retest reliability and minimal detectable change scores for the timed "up & go" test, the six-minute walk test, and gait speed in people with Alzheimer disease. Phys Ther. 2009 Jun;89(6):569-79. doi: 10.2522/ptj.20080258. Epub 2009 Apr 23.
Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther. 2010 Aug 26;2(4):24. doi: 10.1186/alzrt48.
Stavropoulos, T G., G. Meditskos, and I. Kompatsiaris, DemaWare2 AND Integrating sensors, multimedia and semantic analysis for the ambient care of dementia. Pervasive and Mobile Computing, 2017. 34 : p. 126-145.
Swaminathan A, Jicha GA Nutrition and prevention of Alzheimer's dementia. Front Aging Neurosci. 2014 Oct 20;6:282. doi: 10.3389/fnagi.2014.00282. eCollection 2014.
Tarnanas I, Tsolaki A, Wiederhold M, Wiederhold B, Tsolaki M Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps? Alzheimers Dement (Amst). 2015 Nov 14;1(4):521-32. doi: 10.1016/j.dadm.2015.10.005. eCollection 2015 Dec.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.